<!DOCTYPE html>
<html >

<head>

  <meta charset="UTF-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <title>Summary of Conferences 2016</title>
  <meta name="description" content="Conferences mainly regarding clinical pharmacology, pharmacometrics and medicine will be summarized here.">
  <meta name="generator" content="bookdown 0.3.11 and GitBook 2.6.7">

  <meta property="og:title" content="Summary of Conferences 2016" />
  <meta property="og:type" content="book" />
  <meta property="og:url" content="http://shanmdphd.github.io/Conferences/" />
  <meta property="og:image" content="http://shanmdphd.github.io/Conferences/images/cover.png" />
  <meta property="og:description" content="Conferences mainly regarding clinical pharmacology, pharmacometrics and medicine will be summarized here." />
  <meta name="github-repo" content="shanmdphd/shanmdphd.github.io" />

  <meta name="twitter:card" content="summary" />
  <meta name="twitter:title" content="Summary of Conferences 2016" />
  
  <meta name="twitter:description" content="Conferences mainly regarding clinical pharmacology, pharmacometrics and medicine will be summarized here." />
  <meta name="twitter:image" content="http://shanmdphd.github.io/Conferences/images/cover.png" />

<meta name="author" content="Sungpil Han, M.D./Ph.D.">


<meta name="date" content="2017-03-21">

  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta name="apple-mobile-web-app-capable" content="yes">
  <meta name="apple-mobile-web-app-status-bar-style" content="black">
  
  
<link rel="prev" href="the-2nd-a3-pharmacometrics-symposium.html">
<link rel="next" href="kscpt-2016-fall.html">
<script src="libs/jquery/jquery.min.js"></script>
<link href="libs/gitbook/css/style.css" rel="stylesheet" />
<link href="libs/gitbook/css/plugin-bookdown.css" rel="stylesheet" />
<link href="libs/gitbook/css/plugin-highlight.css" rel="stylesheet" />
<link href="libs/gitbook/css/plugin-search.css" rel="stylesheet" />
<link href="libs/gitbook/css/plugin-fontsettings.css" rel="stylesheet" />










<link rel="stylesheet" href="css/style.css" type="text/css" />
</head>

<body>



  <div class="book without-animation with-summary font-size-2 font-family-1" data-basepath=".">

    <div class="book-summary">
      <nav role="navigation">

<ul class="summary">
<li><a href="./">Conferences</a></li>

<li class="divider"></li>
<li class="chapter" data-level="1" data-path="index.html"><a href="index.html"><i class="fa fa-check"></i><b>1</b> Introduction</a></li>
<li class="chapter" data-level="2" data-path="section-2.html"><a href="section-2.html"><i class="fa fa-check"></i><b>2</b> 심장내과</a></li>
<li class="chapter" data-level="3" data-path="-3.html"><a href="-3.html"><i class="fa fa-check"></i><b>3</b> 심장내과 3부</a></li>
<li class="chapter" data-level="4" data-path="cancer-immunotherapy.html"><a href="cancer-immunotherapy.html"><i class="fa fa-check"></i><b>4</b> Cancer immunotherapy</a></li>
<li class="chapter" data-level="5" data-path="bioimaging-2016-04-29.html"><a href="bioimaging-2016-04-29.html"><i class="fa fa-check"></i><b>5</b> Bioimaging 2016-04-29</a></li>
<li class="chapter" data-level="6" data-path="-fda-.html"><a href="-fda-.html"><i class="fa fa-check"></i><b>6</b> 신약개발을 위한 FDA의 바이오이미징 표준화 프로그램 |</a><ul>
<li class="chapter" data-level="6.1" data-path="-fda-.html"><a href="-fda-.html#-center-for-bioimaging-of-new-drug-development-amc"><i class="fa fa-check"></i><b>6.1</b> 김정곤 Center for Bioimaging of New Drug Development AMC</a></li>
</ul></li>
<li class="chapter" data-level="7" data-path="kscpt.html"><a href="kscpt.html"><i class="fa fa-check"></i><b>7</b> 2016 KSCPT</a><ul>
<li class="chapter" data-level="7.1" data-path="kscpt.html"><a href="kscpt.html#first-session"><i class="fa fa-check"></i><b>7.1</b> First Session</a><ul>
<li class="chapter" data-level="7.1.1" data-path="kscpt.html"><a href="kscpt.html#precision-medicine-a-clinical-pharmacological-perspective"><i class="fa fa-check"></i><b>7.1.1</b> 13:20~14:00 Precision Medicine: A Clinical Pharmacological Perspective</a></li>
<li class="chapter" data-level="7.1.2" data-path="kscpt.html"><a href="kscpt.html#the-role-of-pharmacogenomics-in-drug-development-regulatory-review-and-clinical-practice"><i class="fa fa-check"></i><b>7.1.2</b> 14:00~14:30 The role of pharmacogenomics in drug development, regulatory review and clinical practice</a></li>
<li class="chapter" data-level="7.1.3" data-path="kscpt.html"><a href="kscpt.html#the-liver-gut-microbiota-axis-modulates-inter-individual-variability-in-xenobiotic-disposition-and-toxicology"><i class="fa fa-check"></i><b>7.1.3</b> 14:30~15:00 The Liver-Gut Microbiota Axis Modulates Inter-Individual Variability in Xenobiotic Disposition and Toxicology</a></li>
</ul></li>
<li class="chapter" data-level="7.2" data-path="kscpt.html"><a href="kscpt.html#second-session"><i class="fa fa-check"></i><b>7.2</b> Second Session</a><ul>
<li class="chapter" data-level="7.2.1" data-path="kscpt.html"><a href="kscpt.html#the-role-of-stem-cells-in-discovery-and-validation-of-pharmacogenomic-markers"><i class="fa fa-check"></i><b>7.2.1</b> 15:20~15:50 The role of stem cells in discovery and validation of pharmacogenomic markers</a></li>
<li class="chapter" data-level="7.2.2" data-path="kscpt.html"><a href="kscpt.html#pharmacogenomics-and-epigenomics"><i class="fa fa-check"></i><b>7.2.2</b> 15:50~16:20 Pharmacogenomics and Epigenomics</a></li>
<li class="chapter" data-level="7.2.3" data-path="kscpt.html"><a href="kscpt.html#emerging-roles-of-human-cyp1b1-in-cancer-growth-and-metastasis"><i class="fa fa-check"></i><b>7.2.3</b> 16:20~16:50 Emerging roles of human CYP1B1 in cancer growth and metastasis</a></li>
<li class="chapter" data-level="7.2.4" data-path="kscpt.html"><a href="kscpt.html#omics-for-precision-medicine-clinical-implementation-in-oncology"><i class="fa fa-check"></i><b>7.2.4</b> 16:50~17:20 omics for precision Medicine : Clinical Implementation in oncology</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="8" data-path="translation-and-convergence-for-future-medicine.html"><a href="translation-and-convergence-for-future-medicine.html"><i class="fa fa-check"></i><b>8</b> “Translation and Convergence for Future Medicine”</a><ul>
<li class="chapter" data-level="8.1" data-path="translation-and-convergence-for-future-medicine.html"><a href="translation-and-convergence-for-future-medicine.html#plenary-session-ii--rd-"><i class="fa fa-check"></i><b>8.1</b> Plenary Session II “의료기술및 R&amp;D 변화의최신동향”</a><ul>
<li class="chapter" data-level="8.1.1" data-path="translation-and-convergence-for-future-medicine.html"><a href="translation-and-convergence-for-future-medicine.html#lecture-1--------"><i class="fa fa-check"></i><b>8.1.1</b> 13:30 ~ 14:15 Lecture 1 :의료분야에서의 빅데이터 :임상연구 및 진료를 위한 애널리틱스의 활용</a></li>
<li class="chapter" data-level="8.1.2" data-path="translation-and-convergence-for-future-medicine.html"><a href="translation-and-convergence-for-future-medicine.html#lecture-2----"><i class="fa fa-check"></i><b>8.1.2</b> 14:15 ~ 15:00 Lecture 2 :합성 항체에서 합성 단백질로</a></li>
</ul></li>
<li class="chapter" data-level="8.2" data-path="translation-and-convergence-for-future-medicine.html"><a href="translation-and-convergence-for-future-medicine.html#parallel-session-i--chairperson--"><i class="fa fa-check"></i><b>8.2</b> Parallel Session I “의료분야에서의빅데이터” Chairperson :김태원(서울아산병원임상의학연구소장) [대강당]</a><ul>
<li class="chapter" data-level="8.2.1" data-path="translation-and-convergence-for-future-medicine.html"><a href="translation-and-convergence-for-future-medicine.html#lecture-1------alexander-turchin-harvard-university-brigham-and-womens-hospital-usa"><i class="fa fa-check"></i><b>8.2.1</b> Lecture 1 :전자의무기록에 기반한 임상 빅데이터 연구 Alexander Turchin (Harvard University, Brigham and Women’s Hospital, USA)</a></li>
<li class="chapter" data-level="8.2.2" data-path="translation-and-convergence-for-future-medicine.html"><a href="translation-and-convergence-for-future-medicine.html#lecture-2----tom-lawry-microsoft-corp.-usa"><i class="fa fa-check"></i><b>8.2.2</b> Lecture 2 : 의료분야에서의 빅데이터 분석 Tom Lawry (Microsoft Corp., USA)</a></li>
<li class="chapter" data-level="8.2.3" data-path="translation-and-convergence-for-future-medicine.html"><a href="translation-and-convergence-for-future-medicine.html#lecture-3-------"><i class="fa fa-check"></i><b>8.2.3</b> Lecture 3 :생물기작 기반 암 오믹스 데이터 분석 기법</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="9" data-path="acrep.html"><a href="acrep.html"><i class="fa fa-check"></i><b>9</b> ACREP</a><ul>
<li class="chapter" data-level="9.1" data-path="acrep.html"><a href="acrep.html#observational-study"><i class="fa fa-check"></i><b>9.1</b> Observational Study</a><ul>
<li class="chapter" data-level="9.1.1" data-path="acrep.html"><a href="acrep.html#contents"><i class="fa fa-check"></i><b>9.1.1</b> Contents</a></li>
</ul></li>
<li class="chapter" data-level="9.2" data-path="acrep.html"><a href="acrep.html#observational-study-pitfall-----"><i class="fa fa-check"></i><b>9.2</b> Observational Study의 Pitfall 및 이를 극복하기 위한 방법</a><ul>
<li class="chapter" data-level="9.2.1" data-path="acrep.html"><a href="acrep.html#experimental-study-yes"><i class="fa fa-check"></i><b>9.2.1</b> Experimental study? Yes</a></li>
<li class="chapter" data-level="9.2.2" data-path="acrep.html"><a href="acrep.html#experimental-study-no"><i class="fa fa-check"></i><b>9.2.2</b> Experimental study? No</a></li>
<li class="chapter" data-level="9.2.3" data-path="acrep.html"><a href="acrep.html#contents-1"><i class="fa fa-check"></i><b>9.2.3</b> Contents</a></li>
<li class="chapter" data-level="9.2.4" data-path="acrep.html"><a href="acrep.html#conclusion"><i class="fa fa-check"></i><b>9.2.4</b> Conclusion</a></li>
</ul></li>
<li class="chapter" data-level="9.3" data-path="acrep.html"><a href="acrep.html#diagnostic-test-biomarker-study"><i class="fa fa-check"></i><b>9.3</b> Diagnostic test &amp; Biomarker Study</a><ul>
<li class="chapter" data-level="9.3.1" data-path="acrep.html"><a href="acrep.html#contents---diagnostic-test"><i class="fa fa-check"></i><b>9.3.1</b> Contents - Diagnostic test</a></li>
<li class="chapter" data-level="9.3.2" data-path="acrep.html"><a href="acrep.html#contents---biomarker"><i class="fa fa-check"></i><b>9.3.2</b> Contents - Biomarker</a></li>
</ul></li>
<li class="chapter" data-level="9.4" data-path="acrep.html"><a href="acrep.html#----"><i class="fa fa-check"></i><b>9.4</b> 2차 자료원을 이용한 역학 연구군</a></li>
<li class="chapter" data-level="9.5" data-path="acrep.html"><a href="acrep.html#----clinical-prediction-model-individual-riskoutcome-probability--"><i class="fa fa-check"></i><b>9.5</b> 대규모 이차 자료원을 이용한 clinical prediction model : individual risk/outcome probability 예측 분석법</a></li>
<li class="chapter" data-level="9.6" data-path="acrep.html"><a href="acrep.html#web-r.org"><i class="fa fa-check"></i><b>9.6</b> Web-r.org</a><ul>
<li class="chapter" data-level="9.6.1" data-path="acrep.html"><a href="acrep.html#contents-2"><i class="fa fa-check"></i><b>9.6.1</b> Contents</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="10" data-path="prism-2016.html"><a href="prism-2016.html"><i class="fa fa-check"></i><b>10</b> Prism 2016</a><ul>
<li class="chapter" data-level="10.1" data-path="prism-2016.html"><a href="prism-2016.html#morning-session"><i class="fa fa-check"></i><b>10.1</b> Morning Session</a><ul>
<li class="chapter" data-level="10.1.1" data-path="prism-2016.html"><a href="prism-2016.html#lim-covariate-model"><i class="fa fa-check"></i><b>10.1.1</b> Lim Covariate model</a></li>
<li class="chapter" data-level="10.1.2" data-path="prism-2016.html"><a href="prism-2016.html#fda---lee"><i class="fa fa-check"></i><b>10.1.2</b> FDA - Lee</a></li>
<li class="chapter" data-level="10.1.3" data-path="prism-2016.html"><a href="prism-2016.html#pfizer"><i class="fa fa-check"></i><b>10.1.3</b> Pfizer</a></li>
</ul></li>
<li class="chapter" data-level="10.2" data-path="prism-2016.html"><a href="prism-2016.html#afternoon-session"><i class="fa fa-check"></i><b>10.2</b> Afternoon Session</a><ul>
<li class="chapter" data-level="10.2.1" data-path="prism-2016.html"><a href="prism-2016.html#kim"><i class="fa fa-check"></i><b>10.2.1</b> Kim</a></li>
<li class="chapter" data-level="10.2.2" data-path="prism-2016.html"><a href="prism-2016.html#strategic-application-of-pm-in-global-drug-development-experience-from-hanmi"><i class="fa fa-check"></i><b>10.2.2</b> Strategic application of PM in global drug development: Experience from Hanmi</a></li>
<li class="chapter" data-level="10.2.3" data-path="prism-2016.html"><a href="prism-2016.html#mbdd"><i class="fa fa-check"></i><b>10.2.3</b> MBDD</a></li>
<li class="chapter" data-level="10.2.4" data-path="prism-2016.html"><a href="prism-2016.html#pharmacometric-information-in-drug-label"><i class="fa fa-check"></i><b>10.2.4</b> Pharmacometric information in drug label</a></li>
<li class="chapter" data-level="10.2.5" data-path="prism-2016.html"><a href="prism-2016.html#pharmacometrics-in-dose-optimization"><i class="fa fa-check"></i><b>10.2.5</b> Pharmacometrics in Dose Optimization</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="11" data-path="MFDS.html"><a href="MFDS.html"><i class="fa fa-check"></i><b>11</b> MFDS-Asan Joint Symposium on Rare Diseases 2016</a><ul>
<li class="chapter" data-level="11.1" data-path="MFDS.html"><a href="MFDS.html#session-1-rare-diseases-in-korea-status-research-experiences"><i class="fa fa-check"></i><b>11.1</b> Session 1 Rare diseases in Korea : Status &amp; Research experiences</a><ul>
<li class="chapter" data-level="11.1.1" data-path="MFDS.html"><a href="MFDS.html#national-support-for-rare-disease-current-status-and-future-prospects"><i class="fa fa-check"></i><b>11.1.1</b> National support for rare disease : Current status and future prospects</a></li>
<li class="chapter" data-level="11.1.2" data-path="MFDS.html"><a href="MFDS.html#translational-research-for-drug-development-historical-perspective"><i class="fa fa-check"></i><b>11.1.2</b> Translational research for drug development : Historical perspective</a></li>
</ul></li>
<li class="chapter" data-level="11.2" data-path="MFDS.html"><a href="MFDS.html#session-2-global-regulatory-experiences-in-orphan-drug-development"><i class="fa fa-check"></i><b>11.2</b> Session 2 Global regulatory experiences in orphan drug development</a><ul>
<li class="chapter" data-level="11.2.1" data-path="MFDS.html"><a href="MFDS.html#considerations-for-drug-development-for-rare-diseases-cases-of-inborn-errors-of-metabolism"><i class="fa fa-check"></i><b>11.2.1</b> Considerations for drug development for rare diseases : Cases of inborn errors of metabolism</a></li>
<li class="chapter" data-level="11.2.2" data-path="MFDS.html"><a href="MFDS.html#role-of-pharmacometrics-in-the-development-of-orphan-drugs"><i class="fa fa-check"></i><b>11.2.2</b> Role of pharmacometrics in the development of orphan drugs</a></li>
</ul></li>
<li class="chapter" data-level="11.3" data-path="MFDS.html"><a href="MFDS.html#session-3-lessons-and-learned-rd-for-rare-disease"><i class="fa fa-check"></i><b>11.3</b> Session 3 Lessons and learned : R&amp;D for rare disease</a><ul>
<li class="chapter" data-level="11.3.1" data-path="MFDS.html"><a href="MFDS.html#lessons-from-an-orphan-drug-development-i"><i class="fa fa-check"></i><b>11.3.1</b> Lessons from an orphan drug development (I)</a></li>
<li class="chapter" data-level="11.3.2" data-path="MFDS.html"><a href="MFDS.html#lessons-from-an-orphan-drug-development-ii"><i class="fa fa-check"></i><b>11.3.2</b> Lessons from an orphan drug development (II)</a></li>
<li class="chapter" data-level="11.3.3" data-path="MFDS.html"><a href="MFDS.html#case-studies-on-inflammatory-bowel-disease-asan-medical-center"><i class="fa fa-check"></i><b>11.3.3</b> Case studies on inflammatory bowel disease Asan Medical Center</a></li>
<li class="chapter" data-level="11.3.4" data-path="MFDS.html"><a href="MFDS.html#case-studies-on-drug-targets-in-rare-ultra-rare-genetic-disorders"><i class="fa fa-check"></i><b>11.3.4</b> Case studies on drug targets in rare &amp; ultra-rare genetic disorders</a></li>
</ul></li>
<li class="chapter" data-level="11.4" data-path="MFDS.html"><a href="MFDS.html#session-4-asan-initia-tives-for-rare-disease"><i class="fa fa-check"></i><b>11.4</b> Session 4 Asan initia tives for rare disease</a><ul>
<li class="chapter" data-level="11.4.1" data-path="MFDS.html"><a href="MFDS.html#leverage-big-data-to-better-understand-rare-disease-states-and-patient-needs-rare-disease-registry-research-experience"><i class="fa fa-check"></i><b>11.4.1</b> Leverage big data to better understand rare disease states and patient needs (rare disease registry &amp; research experience)</a></li>
<li class="chapter" data-level="11.4.2" data-path="MFDS.html"><a href="MFDS.html#align-commercial-and-development-team-to-forecast-success-through-prism"><i class="fa fa-check"></i><b>11.4.2</b> Align commercial and development team to forecast success through “PRISM”</a></li>
<li class="chapter" data-level="11.4.3" data-path="MFDS.html"><a href="MFDS.html#knowledge-and-perceptions-of-clinical-research-of-patients-suffering-from-rare-diseases"><i class="fa fa-check"></i><b>11.4.3</b> Knowledge and perceptions of clinical research of patients suffering from rare diseases</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="12" data-path="toxicology-2016.html"><a href="toxicology-2016.html"><i class="fa fa-check"></i><b>12</b> Toxicology 2016</a><ul>
<li class="chapter" data-level="12.1" data-path="toxicology-2016.html"><a href="toxicology-2016.html#key-links"><i class="fa fa-check"></i><b>12.1</b> Key links</a></li>
<li class="chapter" data-level="12.2" data-path="toxicology-2016.html"><a href="toxicology-2016.html#session-i-2016-08-22"><i class="fa fa-check"></i><b>12.2</b> Session I 2016-08-22</a><ul>
<li class="chapter" data-level="12.2.1" data-path="toxicology-2016.html"><a href="toxicology-2016.html#---"><i class="fa fa-check"></i><b>12.2.1</b> 독성학 개론 및 발현기전 !!!!</a></li>
<li class="chapter" data-level="12.2.2" data-path="toxicology-2016.html"><a href="toxicology-2016.html#section-12.2.2"><i class="fa fa-check"></i><b>12.2.2</b> 면역독성 !</a></li>
<li class="chapter" data-level="12.2.3" data-path="toxicology-2016.html"><a href="toxicology-2016.html#-"><i class="fa fa-check"></i><b>12.2.3</b> 독성시험과 통계 !!</a></li>
<li class="chapter" data-level="12.2.4" data-path="toxicology-2016.html"><a href="toxicology-2016.html#section-12.2.4"><i class="fa fa-check"></i><b>12.2.4</b> 독성병리 !!</a></li>
<li class="chapter" data-level="12.2.5" data-path="toxicology-2016.html"><a href="toxicology-2016.html#--"><i class="fa fa-check"></i><b>12.2.5</b> 비임상시험결과의 임상시험 연계 !!!!</a></li>
</ul></li>
<li class="chapter" data-level="12.3" data-path="toxicology-2016.html"><a href="toxicology-2016.html#session-ii-2016-08-23"><i class="fa fa-check"></i><b>12.3</b> Session II 2016-08-23</a><ul>
<li class="chapter" data-level="12.3.1" data-path="toxicology-2016.html"><a href="toxicology-2016.html#---"><i class="fa fa-check"></i><b>12.3.1</b> 오믹스 기반을 이용한 독성평가 !</a></li>
<li class="chapter" data-level="12.3.2" data-path="toxicology-2016.html"><a href="toxicology-2016.html#--"><i class="fa fa-check"></i><b>12.3.2</b> 독성동태 및 대사 !!!</a></li>
<li class="chapter" data-level="12.3.3" data-path="toxicology-2016.html"><a href="toxicology-2016.html#--"><i class="fa fa-check"></i><b>12.3.3</b> 유전독성 및 발암성 !!</a></li>
<li class="chapter" data-level="12.3.4" data-path="toxicology-2016.html"><a href="toxicology-2016.html#section-12.3.4"><i class="fa fa-check"></i><b>12.3.4</b> 신경독성 !</a></li>
<li class="chapter" data-level="12.3.5" data-path="toxicology-2016.html"><a href="toxicology-2016.html#--"><i class="fa fa-check"></i><b>12.3.5</b> 식품의 위해도 평가 !</a></li>
<li class="chapter" data-level="12.3.6" data-path="toxicology-2016.html"><a href="toxicology-2016.html#section-12.3.6"><i class="fa fa-check"></i><b>12.3.6</b> 생식발생독성 !</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="13" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><i class="fa fa-check"></i><b>13</b> 2016년 신약임상개발 전문가 과정 “Clinical Research Science Expert Course for Cutting-edge Drug Development”</a><ul>
<li class="chapter" data-level="13.1" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#drug-discovery-and-preclinical-candidate-selection"><i class="fa fa-check"></i><b>13.1</b> Drug discovery and preclinical candidate selection</a><ul>
<li class="chapter" data-level="13.1.1" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#-1st"><i class="fa fa-check"></i><b>13.1.1</b> 김재은 (1ST)</a></li>
</ul></li>
<li class="chapter" data-level="13.2" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#preclinical-development-and-ind-gono-go-decision-using-case-studies"><i class="fa fa-check"></i><b>13.2</b> Preclinical development and IND go/no-go decision (using case studies)</a></li>
<li class="chapter" data-level="13.3" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#global-drug-development-and-interaction-with-regulatory-agencies-fda-emea-using-case-studies"><i class="fa fa-check"></i><b>13.3</b> Global drug development and interaction with regulatory agencies (FDA, EMEA) (using case studies)</a></li>
<li class="chapter" data-level="13.4" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#clinical-pharmacology"><i class="fa fa-check"></i><b>13.4</b> Clinical Pharmacology</a></li>
<li class="chapter" data-level="13.5" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#the-actual-development-and-operation-of-pharmacovigillance-system-in-korean-pharmaceutical-companies"><i class="fa fa-check"></i><b>13.5</b> The actual development and operation of Pharmacovigillance system in Korean pharmaceutical companies</a><ul>
<li class="chapter" data-level="13.5.1" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#experience-of-sop-development-pv-training-sharing-pv-audit-finding"><i class="fa fa-check"></i><b>13.5.1</b> Experience of SOP development &amp; PV training/ Sharing PV audit finding</a></li>
<li class="chapter" data-level="13.5.2" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#establishment-and-application-of-safety-database-system"><i class="fa fa-check"></i><b>13.5.2</b> Establishment and Application of Safety Database System:</a></li>
</ul></li>
<li class="chapter" data-level="13.6" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#open-innovation-in-drug-development"><i class="fa fa-check"></i><b>13.6</b> Open innovation in drug development</a></li>
<li class="chapter" data-level="13.7" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#clinical-development-strategy-and-plan-workshop"><i class="fa fa-check"></i><b>13.7</b> Clinical development strategy and plan workshop</a><ul>
<li class="chapter" data-level="13.7.1" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#course-intro---understanding-tpp-and-hcv"><i class="fa fa-check"></i><b>13.7.1</b> Course intro - Understanding TPP and HCV</a></li>
<li class="chapter" data-level="13.7.2" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#candidate-selection-through-poc"><i class="fa fa-check"></i><b>13.7.2</b> Candidate selection through PoC</a></li>
<li class="chapter" data-level="13.7.3" data-path="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html"><a href="-clinical-research-science-expert-course-for-cutting-edge-drug-development.html#late-phase-development-commercialization"><i class="fa fa-check"></i><b>13.7.3</b> Late phase Development &amp; Commercialization</a></li>
<li class="chapter" data-level="13.7.4" data-path="acrep.html"><a href="acrep.html#----"><i class="fa fa-check"></i><b>13.7.4</b> 국내 사례 소개 및 질의/응답</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="14" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html"><i class="fa fa-check"></i><b>14</b> The 2nd A3 Pharmacometrics Symposium</a><ul>
<li class="chapter" data-level="14.1" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#young-scientist-session"><i class="fa fa-check"></i><b>14.1</b> Young Scientist Session</a><ul>
<li class="chapter" data-level="14.1.1" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#modeling-of-mycoplasma-tuberculosis-biomarkders-for-cure"><i class="fa fa-check"></i><b>14.1.1</b> Modeling of mycoplasma tuberculosis biomarkders for cure</a></li>
<li class="chapter" data-level="14.1.2" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#integrative-pkpd-modling-and-simulation-of-amenamevir-for-treatment-of-recurrent-genital-herpes"><i class="fa fa-check"></i><b>14.1.2</b> Integrative PKPD modling and simulation of Amenamevir for treatment of recurrent genital herpes</a></li>
<li class="chapter" data-level="14.1.3" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#model-based-meta-analysis-to-quantify-and-compare-the-efficacy-of-non-hormonal-drugs-on-menopausal-hot-flashes"><i class="fa fa-check"></i><b>14.1.3</b> Model Based Meta-Analysis to quantify and compare the efficacy of non-hormonal drugs on menopausal Hot flashes</a></li>
<li class="chapter" data-level="14.1.4" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#dosing-optimization-in-obesity-using-pharmacometrics-approach-population-pk-and-pd-of-meropenem-in-non-obese-obese-and-mobidly-obese-patients"><i class="fa fa-check"></i><b>14.1.4</b> Dosing optimization in obesity using pharmacometrics approach: population PK and PD of meropenem in non-obese, obese and mobidly obese patients</a></li>
</ul></li>
<li class="chapter" data-level="14.2" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#application-session"><i class="fa fa-check"></i><b>14.2</b> Application Session</a><ul>
<li class="chapter" data-level="14.2.1" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#the-application-of-pharmacometrics-in-individual-therapy-in-china"><i class="fa fa-check"></i><b>14.2.1</b> The application of pharmacometrics in individual therapy in China</a></li>
<li class="chapter" data-level="14.2.2" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#pd-model-fo-bayesian-prediction-of-myelosuppression-rpofiles-based-on-routine-clinical-data-after-gemcitabine-and-carboplatin-treatment"><i class="fa fa-check"></i><b>14.2.2</b> PD model fo Bayesian Prediction of myelosuppression rpofiles based on routine clinical data after gemcitabine and carboplatin treatment</a></li>
<li class="chapter" data-level="14.2.3" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#modeling-and-validating-chronic-pharmacological-manupulation-of-circadian-rhythms"><i class="fa fa-check"></i><b>14.2.3</b> Modeling and validating chronic pharmacological manupulation of circadian rhythms</a></li>
<li class="chapter" data-level="14.2.4" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#application-of-pkpd-modeling-and-simulation-in-antiviral-drug-development"><i class="fa fa-check"></i><b>14.2.4</b> Application of PK/PD modeling and simulation in antiviral drug development</a></li>
<li class="chapter" data-level="14.2.5" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#pharmacometrics-in-clinical-practice-pop-pk-analysis-of-febuxostat-in-patients-with-severe-renal-impairment"><i class="fa fa-check"></i><b>14.2.5</b> pharmacometrics in clinical practice: pop PK analysis of febuxostat in patients with severe renal impairment</a></li>
</ul></li>
<li class="chapter" data-level="14.3" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#regulation"><i class="fa fa-check"></i><b>14.3</b> Regulation</a><ul>
<li class="chapter" data-level="14.3.1" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#the-new-japanese-guideline-on-population-pk-and-pd-analysis"><i class="fa fa-check"></i><b>14.3.1</b> The new Japanese guideline on population PK and PD analysis</a></li>
<li class="chapter" data-level="14.3.2" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#how-to-increase-the-number-of-population-pk-analysis-reports-submitted-to-mfds-in-korea"><i class="fa fa-check"></i><b>14.3.2</b> How to increase the number of population PK analysis reports submitted to MFDS in Korea</a></li>
<li class="chapter" data-level="14.3.3" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#ema-regulations-on-meling-issues"><i class="fa fa-check"></i><b>14.3.3</b> EMA regulations on meling issues</a></li>
<li class="chapter" data-level="14.3.4" data-path="the-2nd-a3-pharmacometrics-symposium.html"><a href="the-2nd-a3-pharmacometrics-symposium.html#recent-examples-of-impact-of-pharmacometrics-in-decision-making"><i class="fa fa-check"></i><b>14.3.4</b> Recent examples of impact of pharmacometrics in decision making</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="15" data-path="asrm-2016.html"><a href="asrm-2016.html"><i class="fa fa-check"></i><b>15</b> ASRM 2016</a><ul>
<li class="chapter" data-level="15.1" data-path="asrm-2016.html"><a href="asrm-2016.html#plenary-lectures"><i class="fa fa-check"></i><b>15.1</b> Plenary lectures</a><ul>
<li class="chapter" data-level="15.1.1" data-path="asrm-2016.html"><a href="asrm-2016.html#plenary-2"><i class="fa fa-check"></i><b>15.1.1</b> Plenary 2</a></li>
<li class="chapter" data-level="15.1.2" data-path="asrm-2016.html"><a href="asrm-2016.html#plenary-lecture-3-the-importance-of-long-acting-reversible-contraception-larc"><i class="fa fa-check"></i><b>15.1.2</b> Plenary Lecture 3 : The importance of Long-acting reversible contraception (LARC)</a></li>
<li class="chapter" data-level="15.1.3" data-path="asrm-2016.html"><a href="asrm-2016.html#plenary-4"><i class="fa fa-check"></i><b>15.1.3</b> Plenary 4</a></li>
<li class="chapter" data-level="15.1.4" data-path="asrm-2016.html"><a href="asrm-2016.html#plenary-5"><i class="fa fa-check"></i><b>15.1.4</b> Plenary 5</a></li>
<li class="chapter" data-level="15.1.5" data-path="asrm-2016.html"><a href="asrm-2016.html#plenary-6-update-on-congenital-adrenal-hyperplasia"><i class="fa fa-check"></i><b>15.1.5</b> Plenary 6 Update on Congenital Adrenal Hyperplasia</a></li>
<li class="chapter" data-level="15.1.6" data-path="asrm-2016.html"><a href="asrm-2016.html#plenary-7---why-parents-matter-epigenetically-genomic-imprinting-in-health-and-disease"><i class="fa fa-check"></i><b>15.1.6</b> Plenary 7 - Why Parents Matter (Epigenetically): Genomic Imprinting in Health and Disease</a></li>
<li class="chapter" data-level="15.1.7" data-path="asrm-2016.html"><a href="asrm-2016.html#plenary-8-aua-bruce-stewart-memorial-lecture-the-futures-of-malereproductive-medicine"><i class="fa fa-check"></i><b>15.1.7</b> Plenary 8: AUA Bruce Stewart Memorial Lecture: The Futures of (Male(Reproductive)) Medicine</a></li>
</ul></li>
<li class="chapter" data-level="15.2" data-path="asrm-2016.html"><a href="asrm-2016.html#prize-oral"><i class="fa fa-check"></i><b>15.2</b> Prize Oral</a><ul>
<li class="chapter" data-level="15.2.1" data-path="asrm-2016.html"><a href="asrm-2016.html#mtor-inhibitors-preserve-fertility-in-a-murine-model-a-novel-pharmacologic-approach-to-fertility-preservation-during-gonadotoxic-chemotherapy"><i class="fa fa-check"></i><b>15.2.1</b> mTOR inhibitors preserve fertility in a murine model : a novel pharmacologic approach to fertility preservation during gonadotoxic chemotherapy</a></li>
<li class="chapter" data-level="15.2.2" data-path="asrm-2016.html"><a href="asrm-2016.html#verification-of-accuracy-safety-for-ovarian-reserve-assessment-with-optical-coherence-tomography-using-mouse-ovary"><i class="fa fa-check"></i><b>15.2.2</b> Verification of accuracy &amp; safety for ovarian reserve assessment with optical coherence tomography using mouse ovary</a></li>
<li class="chapter" data-level="15.2.3" data-path="asrm-2016.html"><a href="asrm-2016.html#o-6-randomized-controlled-trial-of-low-5-vs.-ultralow-2-oxygen-tension-for-in-vitro-development-of-human-embryos"><i class="fa fa-check"></i><b>15.2.3</b> O-6 RANDOMIZED CONTROLLED TRIAL OF LOW (5%) VS. ULTRALOW (2%) OXYGEN TENSION FOR IN VITRO DEVELOPMENT OF HUMAN EMBRYOS</a></li>
</ul></li>
<li class="chapter" data-level="15.3" data-path="asrm-2016.html"><a href="asrm-2016.html#symposium-overview-of-food-and-drug-administration-fda-regulations-of-products-used-to-treat-reproductive-conditions-in-women"><i class="fa fa-check"></i><b>15.3</b> Symposium : Overview of Food and Drug Administration (FDA) Regulations of Products Used to Treat Reproductive Conditions in Women</a><ul>
<li class="chapter" data-level="15.3.1" data-path="asrm-2016.html"><a href="asrm-2016.html#richard-d.-mcfarland-m.d.-ph.d."><i class="fa fa-check"></i><b>15.3.1</b> Richard D. McFarland, M.D., Ph.D.</a></li>
<li class="chapter" data-level="15.3.2" data-path="asrm-2016.html"><a href="asrm-2016.html#rhonda---cder-drug-review-process"><i class="fa fa-check"></i><b>15.3.2</b> Rhonda - CDER Drug review process</a></li>
<li class="chapter" data-level="15.3.3" data-path="asrm-2016.html"><a href="asrm-2016.html#cdrh-center-for-devices-and-radiological-health"><i class="fa fa-check"></i><b>15.3.3</b> CDRH (Center for Devices and Radiological Health)</a></li>
<li class="chapter" data-level="15.3.4" data-path="asrm-2016.html"><a href="asrm-2016.html#endometriosis-tuesday-expo-theater"><i class="fa fa-check"></i><b>15.3.4</b> Endometriosis, Tuesday EXPO theater</a></li>
</ul></li>
<li class="chapter" data-level="15.4" data-path="asrm-2016.html"><a href="asrm-2016.html#scientific-congress-prize-paper-session-2"><i class="fa fa-check"></i><b>15.4</b> Scientific Congress Prize Paper Session 2</a><ul>
<li class="chapter" data-level="15.4.1" data-path="asrm-2016.html"><a href="asrm-2016.html#o-91-preovulatory-protein-restriction-ppr-disrupted-amino-acid-aa-kinetics-and-mitochondrial-structure-and-function-in-the-rat-oocyte"><i class="fa fa-check"></i><b>15.4.1</b> O-91 PREOVULATORY PROTEIN RESTRICTION (PPR): DISRUPTED AMINO ACID (AA) KINETICS AND MITOCHONDRIAL STRUCTURE AND FUNCTION IN THE RAT OOCYTE</a></li>
<li class="chapter" data-level="15.4.2" data-path="asrm-2016.html"><a href="asrm-2016.html#o-92-effects-of-resveratrol-on-polycystic-ovary-syndrome"><i class="fa fa-check"></i><b>15.4.2</b> O-92 EFFECTS OF RESVERATROL ON POLYCYSTIC OVARY SYNDROME</a></li>
<li class="chapter" data-level="15.4.3" data-path="asrm-2016.html"><a href="asrm-2016.html#o-93-genome-wide-dna-methylation-changes-in-mouse-zygotes-associated-with-superovulation"><i class="fa fa-check"></i><b>15.4.3</b> O-93 GENOME-WIDE DNA METHYLATION CHANGES IN MOUSE ZYGOTES ASSOCIATED WITH SUPEROVULATION</a></li>
<li class="chapter" data-level="15.4.4" data-path="asrm-2016.html"><a href="asrm-2016.html#o-94-can-we-expect-to-improve-age-at-menopause-predictions-with-repeated-amh-measurements"><i class="fa fa-check"></i><b>15.4.4</b> O-94 CAN WE EXPECT TO IMPROVE AGE AT MENOPAUSE PREDICTIONS WITH REPEATED AMH MEASUREMENTS?</a></li>
</ul></li>
<li class="chapter" data-level="15.5" data-path="asrm-2016.html"><a href="asrm-2016.html#oral-presentation"><i class="fa fa-check"></i><b>15.5</b> Oral Presentation</a><ul>
<li class="chapter" data-level="15.5.1" data-path="asrm-2016.html"><a href="asrm-2016.html#o-229-the-impact-of-elagolix-on-quality-of-life-in-women-with-endometriosis-associated-pain-results-from-two-randomized-placebo-controlled-studies-using-the-endometriosis-health-profile-questionnaire-hugh-taylor"><i class="fa fa-check"></i><b>15.5.1</b> O-229 THE IMPACT OF ELAGOLIX ON QUALITY OF LIFE IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN: RESULTS FROM TWO RANDOMIZED, PLACEBO-CONTROLLED STUDIES USING THE ENDOMETRIOSIS HEALTH PROFILE QUESTIONNAIRE (Hugh Taylor)</a></li>
<li class="chapter" data-level="15.5.2" data-path="asrm-2016.html"><a href="asrm-2016.html#o-230-direct-and-indirect-costs-associated-with-endometriosis-related-surgery-among-employed-women-in-the-us"><i class="fa fa-check"></i><b>15.5.2</b> O-230 DIRECT AND INDIRECT COSTS ASSOCIATED WITH ENDOMETRIOSIS-RELATED SURGERY AMONG EMPLOYED WOMEN IN THE US</a></li>
<li class="chapter" data-level="15.5.3" data-path="asrm-2016.html"><a href="asrm-2016.html#o-231-new-procedure-for-the-endometriosis-diagnosis"><i class="fa fa-check"></i><b>15.5.3</b> O-231 NEW PROCEDURE FOR THE ENDOMETRIOSIS DIAGNOSIS</a></li>
<li class="chapter" data-level="15.5.4" data-path="asrm-2016.html"><a href="asrm-2016.html#o-232-elagolix-on-endometrium"><i class="fa fa-check"></i><b>15.5.4</b> O-232 Elagolix on endometrium</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="16" data-path="kscpt-2016-fall.html"><a href="kscpt-2016-fall.html"><i class="fa fa-check"></i><b>16</b> KSCPT 2016 Fall</a><ul>
<li class="chapter" data-level="16.1" data-path="kscpt-2016-fall.html"><a href="kscpt-2016-fall.html#therapeutics-new-target"><i class="fa fa-check"></i><b>16.1</b> Therapeutics : New target</a><ul>
<li class="chapter" data-level="16.1.1" data-path="kscpt-2016-fall.html"><a href="kscpt-2016-fall.html#a-new-target-for-hiv-1-aids-drug"><i class="fa fa-check"></i><b>16.1.1</b> A new target for HIV-1 / AIDS drug</a></li>
<li class="chapter" data-level="16.1.2" data-path="kscpt-2016-fall.html"><a href="kscpt-2016-fall.html#new-drug-target-for-osteoporosis-gpr120"><i class="fa fa-check"></i><b>16.1.2</b> New drug target for osteoporosis: GPR120</a></li>
<li class="chapter" data-level="16.1.3" data-path="kscpt-2016-fall.html"><a href="kscpt-2016-fall.html#strategy-for-anti-cancer-target"><i class="fa fa-check"></i><b>16.1.3</b> Strategy for Anti-Cancer Target</a></li>
<li class="chapter" data-level="16.1.4" data-path="toxicology-2016.html"><a href="toxicology-2016.html#--"><i class="fa fa-check"></i><b>16.1.4</b> 재발자궁경부암 항암화학방사선 온열동시치료</a></li>
</ul></li>
<li class="chapter" data-level="16.2" data-path="kscpt-2016-fall.html"><a href="kscpt-2016-fall.html#drug-development-i"><i class="fa fa-check"></i><b>16.2</b> Drug development I</a><ul>
<li class="chapter" data-level="16.2.1" data-path="kscpt-2016-fall.html"><a href="kscpt-2016-fall.html#non-clinical-considerations-for-fih"><i class="fa fa-check"></i><b>16.2.1</b> Non-clinical considerations for FIH</a></li>
<li class="chapter" data-level="16.2.2" data-path="kscpt-2016-fall.html"><a href="kscpt-2016-fall.html#------"><i class="fa fa-check"></i><b>16.2.2</b> 임상약리학 주도 환자 대상 초기임상시험의 경험과 전망</a></li>
<li class="chapter" data-level="16.2.3" data-path="kscpt-2016-fall.html"><a href="kscpt-2016-fall.html#the-contribution-of-clinical-pharmacologist-in-global-drug-development-real-examples-from-a-big-pharma"><i class="fa fa-check"></i><b>16.2.3</b> The Contribution of Clinical Pharmacologist in Global Drug Development: Real Examples from a Big Pharma</a></li>
</ul></li>
<li class="chapter" data-level="16.3" data-path="kscpt-2016-fall.html"><a href="kscpt-2016-fall.html#drug-development-ii--"><i class="fa fa-check"></i><b>16.3</b> Drug development II 신상구 (차바이오컴플렉스)</a><ul>
<li class="chapter" data-level="16.3.1" data-path="kscpt-2016-fall.html"><a href="kscpt-2016-fall.html#babe------vs-"><i class="fa fa-check"></i><b>16.3.1</b> BA/BE 임상시험 결과분석 시 고려사항: 분산투여 vs 추가시험</a></li>
<li class="chapter" data-level="16.3.2" data-path="kscpt-2016-fall.html"><a href="kscpt-2016-fall.html#the-use-of-pharmacometrics-for-drug-development-in-korea"><i class="fa fa-check"></i><b>16.3.2</b> The use of pharmacometrics for drug development in Korea</a></li>
<li class="chapter" data-level="16.3.3" data-path="kscpt-2016-fall.html"><a href="kscpt-2016-fall.html#fatal-bia-10-2474-phase-i-clinical-trial-what-can-we-learn"><i class="fa fa-check"></i><b>16.3.3</b> Fatal BIA 10-2474 Phase I Clinical Trial : What Can We Learn?</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="17" data-path="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html"><a href="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html"><i class="fa fa-check"></i><b>17</b> 2016-11-18 Will big data and data science reshape the horizon of drug development?, If so, how?</a><ul>
<li class="chapter" data-level="17.1" data-path="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html"><a href="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html#jscpt"><i class="fa fa-check"></i><b>17.1</b> JSCPT</a><ul>
<li class="chapter" data-level="17.1.1" data-path="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html"><a href="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html#--------"><i class="fa fa-check"></i><b>17.1.1</b> 대규모 약물 유도 전사체 정보 기반 항암 신약 재창출</a></li>
<li class="chapter" data-level="17.1.2" data-path="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html"><a href="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html#big-data-platform-for-multi-national-data-collaboration"><i class="fa fa-check"></i><b>17.1.2</b> Big data platform for multi-national data collaboration</a></li>
<li class="chapter" data-level="17.1.3" data-path="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html"><a href="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html#yoshinori-ochiai-pharmaceuticals-and-medical-devices-agency"><i class="fa fa-check"></i><b>17.1.3</b> Yoshinori Ochiai (Pharmaceuticals and Medical Devices Agency)</a></li>
<li class="chapter" data-level="17.1.4" data-path="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html"><a href="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html#how-big-data-national-registry-data-can-be-a-game-changer"><i class="fa fa-check"></i><b>17.1.4</b> How big data (national registry data) can be a game changer?</a></li>
</ul></li>
<li class="chapter" data-level="17.2" data-path="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html"><a href="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html#how-can-clinical-pharmacology-facilitate-collaboration-between-the-drug-development-industry-and-academia-particularly-in-the-asian-pacific-region"><i class="fa fa-check"></i><b>17.2</b> How can clinical pharmacology facilitate collaboration between the drug development industry and academia, particularly in the Asian-Pacific region?</a><ul>
<li class="chapter" data-level="17.2.1" data-path="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html"><a href="will-big-data-and-data-science-reshape-the-horizon-of-drug-development-if-so-how.html#thyroid"><i class="fa fa-check"></i><b>17.2.1</b> Thyroid</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="18" data-path="section.html"><a href="section.html"><i class="fa fa-check"></i><b>18</b> 2017-03-20</a></li>
<li class="chapter" data-level="19" data-path="reference.html"><a href="reference.html"><i class="fa fa-check"></i><b>19</b> Reference</a></li>
<li class="divider"></li>
<li><a href="http://shanmdphd.github.io">Back to shanmdphd.github.io</a></li>

</ul>

      </nav>
    </div>

    <div class="book-body">
      <div class="body-inner">
        <div class="book-header" role="navigation">
          <h1>
            <i class="fa fa-circle-o-notch fa-spin"></i><a href="./">Summary of Conferences 2016</a>
          </h1>
        </div>

        <div class="page-wrapper" tabindex="-1" role="main">
          <div class="page-inner">

            <section class="normal" id="section-">
<div id="asrm-2016" class="section level1">
<h1><span class="header-section-number">Chapter 15</span> ASRM 2016</h1>
<p>ASRM 2016은 미국생식의학회에서 주최하는 생식의학 관련 가장 큰 학회입니다.</p>
<p><a href="https://drive.google.com/open?id=0B7BS_yg2ja1EeUFxWkxFWVU3dEE" class="uri">https://drive.google.com/open?id=0B7BS_yg2ja1EeUFxWkxFWVU3dEE</a></p>
<div class="figure">
<img src="https://lh3.googleusercontent.com/HE0f-tEFU59NQS-fFg5bt5BQXJ1mGOoSzMaTMfODF8QU1sro-2hkkfh72F8UqjV4YUGLnhHlrZ_ZT_TNkRIu1w=w1280-h608-rw" />

</div>
<div id="plenary-lectures" class="section level2">
<h2><span class="header-section-number">15.1</span> Plenary lectures</h2>
<div id="plenary-2" class="section level3">
<h3><span class="header-section-number">15.1.1</span> Plenary 2</h3>
<ul>
<li>speaker: Camran Nezhat, M.D. Lectureship in Innovations in Medicine</li>
<li>speaker: Diana W. Bianchi, M.D. Tufts University School of Medicine (NICHD director, soon-to-be)</li>
<li>Maternal Plasma DNA Sequencing</li>
<li>Noninvasive prenatal genetic testing using analysis of cell-free DNA in maternal plasma has translated to and transformed clinical care.</li>
<li>importance of positive and negative predictive values</li>
</ul>
</div>
<div id="plenary-lecture-3-the-importance-of-long-acting-reversible-contraception-larc" class="section level3">
<h3><span class="header-section-number">15.1.2</span> Plenary Lecture 3 : The importance of Long-acting reversible contraception (LARC)</h3>
<ul>
<li>speaker: Jeffrey F. Peipert (Indiana University)</li>
<li>Unintended pregnancy = High-risk pregnancy
<ul>
<li>Less likely to seek prenatal management</li>
</ul></li>
<li>Huge difference among countries - Sexual activity = Similar (US and Sweden)</li>
<li>Teen birth 는 감소하고 있다.</li>
<li>Common contraceptive method - OCP, Sterilization , Condom, Vasectomy</li>
<li>IUD, DMPA, Implant - highly effective</li>
<li>LNG-IUS ~ 5y, Copper ~ 10y, Implnat - 3y</li>
<li>Myths - infection, infertility, pain, cancer,
<ul>
<li>Providers - litigation fear</li>
</ul></li>
<li>Safety
<ul>
<li>IUD does not cause PID (Only first month)</li>
<li>IUD does not cause infertility (Chlamydia - infertility)</li>
<li>Etopic pregnancy - Actually reduce!</li>
<li>Actually lower risk of endometrial, cervical cancer</li>
</ul></li>
<li>Poor candidates for IUD - puerperal sepsis, post septic abortion, unexplained vaginal bleeding, current cervitis, chlamydia</li>
<li>Adolescents - encourage use of dual</li>
<li>Etonogestrel implant - subdermally implant (NEXPLANON)
<ul>
<li>inhibits ovulation</li>
<li>&lt;1%</li>
<li>didn’t vary by BMI status</li>
<li>discontinuation - bleeding irregulatities</li>
</ul></li>
<li>Contraceptive Choice Project
<ul>
<li>Promote LARC use</li>
<li>50% believe IUC is safe</li>
<li>10,000 participants (4 years) CHOICE study</li>
<li>2000 teenagers</li>
<li>75% chose LARC.</li>
<li>NEJM published (2 papers)</li>
<li>Very reliable - especially teenagers</li>
<li>Decreased repeated abortion</li>
<li>Race disparity can be minimized.</li>
</ul></li>
<li>Edutcation, Access, Costs &amp; LARC-friendly providers</li>
<li>Dissemination strategies - Short videos</li>
</ul>
<p><strong>Summary</strong></p>
<ul>
<li>Unintended pregnancy and teen pregnancy continue to be important health problems in the United States.</li>
<li>Long-acting reversible contraception (LARC) is one strategy that has proven to be effective, yet underutilized.</li>
</ul>
</div>
<div id="plenary-4" class="section level3">
<h3><span class="header-section-number">15.1.3</span> Plenary 4</h3>
<ul>
<li>speaker: Jay Ross Kaplan, Ph.D. Wake Forest School of Medicine</li>
<li>CV (CHD and stroke) - not just for men</li>
<li>WISE study - endogenous estradiol in premenopausal women w or wo CHD</li>
<li>Conclusions from epidemiology of sex differences in CHD</li>
<li>Pre- and sugically postmenopausal monkeys</li>
<li>Subclinical ovarian dysfunction - relatively common in premenopausal monkeys - precocious acceleration of atherosclerosis.</li>
<li>Exogenous hormones (OCs) mitigate this effect.</li>
<li>Estrogen treatment immediately following ovariectomy inhibits atheosclerosis; <strong>delayed treatment ineffective</strong> - perhaps because lesions are larger.</li>
<li>CHD risk in pre- and early post-menopausal women - ELITE tiral and numerous re-examinations of existing trials.</li>
</ul>
</div>
<div id="plenary-5" class="section level3">
<h3><span class="header-section-number">15.1.4</span> Plenary 5</h3>
<ul>
<li>speaker: Jan Deprest, M.D., Ph.D., F.R.C.O.G. - University of Leuven</li>
<li>Fetal surgery</li>
<li>Obstetical endoscopy - TTTS</li>
<li>Angiogram showed “Third” circulation.</li>
<li>“Chorangiopagus” - donor (oligohydramnios) recipient (polyhydramnios)</li>
<li>Ultrasound screening programs can pick up congenital malformations, of which some are eligible for prenatal surgical repair.</li>
<li><strong>Some procedures are possible by fetoscopy</strong>, while others require a hysterotomy.</li>
<li>impact of fetal surgery on the future reproductive life of the mother</li>
<li>MOMS trial - 12mo outcomes (prenatal surgery, postnatal surgery) - uterine dehiscence (10%) !!!!</li>
<li>Congenital diaphragmatic hernia - lethal pulmonary hypoplasia - fetoscopic surgery (tracheal occlusion)</li>
</ul>
<p><strong>Future</strong></p>
<ul>
<li>Fetal surgery - fails in ~40% of cases -&gt; Novel target discovery - gene expression analysis</li>
<li>Explorer candidate medical Tx. -&gt; Viagra</li>
</ul>
<p><strong>Conclusion</strong></p>
<ul>
<li>Fetoscopy is a clinical reality (few materal Cx &lt;1%)</li>
<li>Open surgery (high materal morbidity)</li>
</ul>
</div>
<div id="plenary-6-update-on-congenital-adrenal-hyperplasia" class="section level3">
<h3><span class="header-section-number">15.1.5</span> Plenary 6 Update on Congenital Adrenal Hyperplasia</h3>
<ul>
<li>Maria I. New, M.D. -&gt; Icahn School of Medicine at Mount Sinai</li>
<li>SRY (Y chromosome) Sertoli - MIF (Mullerian Inhibiting Factor -&gt; supress tubes) -&gt; Mullerian regression
<ul>
<li>Leydig cells -&gt; testosterone -&gt; DHT (Penis, scrotum)</li>
</ul></li>
<li>17OH Progesterone (CAH screening)</li>
</ul>
<div class="figure">
<img src="http://www.aafp.org/afp/1999/0301/afp19990301p1190-f2.gif" />

</div>
<iframe width="560" height="315" src="https://www.youtube.com/embed/XjtTN96V1rM" frameborder="0" allowfullscreen>
</iframe>
<ul>
<li>bone age advancement, rapid growth</li>
<li>Classical diseases</li>
<li>Congenital adrenal hyperplasia is a common inherited form of <strong>adrenal insufficiency</strong> due to mutations (genetic defects) in the genes coding for several enzymes needed to produce vital adrenal cortex hormones.</li>
<li>such as drug therapy with androgen-blocking effects and growth hormone to delay puberty, as well as surgical options, including prenatal therapy.</li>
</ul>
</div>
<div id="plenary-7---why-parents-matter-epigenetically-genomic-imprinting-in-health-and-disease" class="section level3">
<h3><span class="header-section-number">15.1.6</span> Plenary 7 - Why Parents Matter (Epigenetically): Genomic Imprinting in Health and Disease</h3>
<ul>
<li>Marisa S. Bartolomei, Ph.D.</li>
</ul>
</div>
<div id="plenary-8-aua-bruce-stewart-memorial-lecture-the-futures-of-malereproductive-medicine" class="section level3">
<h3><span class="header-section-number">15.1.7</span> Plenary 8: AUA Bruce Stewart Memorial Lecture: The Futures of (Male(Reproductive)) Medicine</h3>
<ul>
<li>Craig Niederberger, M.D., F.A.C.S.</li>
<li>stackoverflow - <a href="http://stackoverflow.com/users/708833/dribbler">advance all elements in a Range in Swift</a></li>
<li>WOLFRAM Mathematica</li>
<li>second order differential mathematics</li>
<li><a href="https://www.wolframalpha.com/">Wolfram Alpha</a></li>
<li>Raspberry Pi</li>
<li><a href="https://www.raspberrypi.org/blog/raspberry-pi-zero/">RASPBERRY PI ZERO: THE $5 COMPUTER</a></li>
<li>Medical Therapy - prior to TESE</li>
<li>the future of reproductive medicine</li>
<li>Urine pressure checker by Raspberry Pi</li>
<li>Sperm analysis by automated machine</li>
<li>Future shock by Alvin Toffler</li>
</ul>
</div>
</div>
<div id="prize-oral" class="section level2">
<h2><span class="header-section-number">15.2</span> Prize Oral</h2>
<div id="mtor-inhibitors-preserve-fertility-in-a-murine-model-a-novel-pharmacologic-approach-to-fertility-preservation-during-gonadotoxic-chemotherapy" class="section level3">
<h3><span class="header-section-number">15.2.1</span> mTOR inhibitors preserve fertility in a murine model : a novel pharmacologic approach to fertility preservation during gonadotoxic chemotherapy</h3>
<ul>
<li>Kara Goldmann (NYU) Schneider lab</li>
<li>diminished ovarian reserve</li>
<li>PI3K -&gt; AKT -&gt; mTORC1</li>
<li>mTORC1 inhibitors (Everolimus) - breast cancer</li>
<li>mTOR inhibitor 단독은 부작용 있지만, cyclophosphamide가 ovarian reserve를 보존할 수 있다</li>
<li>rodent experiment</li>
<li>AMH - (when increased, ovarian reserve decreased)</li>
<li>Cytoxan단독은 AMH 낮추나 복합은 여전히 높아져 있음</li>
<li>RAD INK daily CY(cyclophosphamide) RAD+CY INK+CK</li>
<li>mTOR inhibitors preserved fertility</li>
</ul>
</div>
<div id="verification-of-accuracy-safety-for-ovarian-reserve-assessment-with-optical-coherence-tomography-using-mouse-ovary" class="section level3">
<h3><span class="header-section-number">15.2.2</span> Verification of accuracy &amp; safety for ovarian reserve assessment with optical coherence tomography using mouse ovary</h3>
<ul>
<li>Seido Takae</li>
<li>establishment of standard follicle imaging</li>
<li>Safety of OCT - No impact on IVF outcome</li>
<li>Clinical Trial - vitrification - aplastic anemia (15/F)</li>
<li>Young cancer or POI patient can be benefited (Ovariectomy)</li>
<li>Laparoscopy</li>
</ul>
</div>
<div id="o-6-randomized-controlled-trial-of-low-5-vs.-ultralow-2-oxygen-tension-for-in-vitro-development-of-human-embryos" class="section level3">
<h3><span class="header-section-number">15.2.3</span> O-6 RANDOMIZED CONTROLLED TRIAL OF LOW (5%) VS. ULTRALOW (2%) OXYGEN TENSION FOR IN VITRO DEVELOPMENT OF HUMAN EMBRYOS</h3>
<ul>
<li>speaker: Daniel Kaser</li>
<li>5% - oviduct</li>
<li>2% - uterine</li>
<li>How about culturing environment? 배양도 같은 방법으로 해야 하나?</li>
<li>Design : 5% O2 (D1-D3) -&gt; 5% vs 2% O2 (D4~ )</li>
<li>Primary endpoint: Embryo stage and grade</li>
<li>Secondary endpoint: Spent media analyses</li>
<li>These findings support our hypothesis that blastocyst yield and quality may be superior when O2 tension is reduced from 5% to 2% on day 3, thereby recapitulating the O2 environment in vivo.</li>
</ul>
</div>
</div>
<div id="symposium-overview-of-food-and-drug-administration-fda-regulations-of-products-used-to-treat-reproductive-conditions-in-women" class="section level2">
<h2><span class="header-section-number">15.3</span> Symposium : Overview of Food and Drug Administration (FDA) Regulations of Products Used to Treat Reproductive Conditions in Women</h2>
<ul>
<li>panel: Yun-shang Piao, Ph.D., R.A.C., Rhonda M. Hearns-Stewart, M.D., Shelley R. Slaughter, M.D., Ph.D., Monica Garcia, Ph.D., Michael T. Bailey, Ph.D.</li>
</ul>
<div id="richard-d.-mcfarland-m.d.-ph.d." class="section level3">
<h3><span class="header-section-number">15.3.1</span> Richard D. McFarland, M.D., Ph.D.</h3>
<ul>
<li>OTAT - Office of Tissues and Advanced Therapies</li>
<li>Cellular therapies, Cancer vaccines etc</li>
<li>Human cells, Tissues (HCT/Ps)</li>
<li>Two regulatory tiers
<ul>
<li>“361 HCT/P”</li>
<li>Drugs, devices and/or biological products</li>
</ul></li>
<li>2667 registered (mostly HPC, blood bank)</li>
<li>Relavant communicable disease agents or disease (RCDADs) - HIV-1,2, HBV, HBC, syphilis,</li>
<li>Donor eligibility (DE) determination
<ul>
<li>DE exception (Cells and tissue for autologous use, by sexually intimate partner..)</li>
</ul></li>
<li>Recent final guideline
<ul>
<li>Syphilis Testing - FDA-licensed, approved or cleared donor screening tests</li>
<li>WNV(West Nile Virus) Testing - licensed NAT donor screening test (June - Sep)</li>
<li>HBV NAT - FDA-licensed NAT donor screening test</li>
<li>ZIKV Screening - immediate implementation guidance</li>
</ul></li>
<li>지금까지는 Subpart C, 지금부터는 Subpart A</li>
</ul>
</div>
<div id="rhonda---cder-drug-review-process" class="section level3">
<h3><span class="header-section-number">15.3.2</span> Rhonda - CDER Drug review process</h3>
<ul>
<li>speaker: Rhonda</li>
<li>Important regulatory milestones
<ul>
<li>1906 - Pure Food Drugs Act</li>
<li>1938 - FDC (The Act)</li>
<li>1951 - Durham-Humphrey Amendment - prescription drug (habit forming, potentially harming drug)</li>
<li>1962 - Kefauver-Harris Drug Amendment - all new drugs must also establish efficacy</li>
<li>1984 - Hatch</li>
<li>1992 - prescription drug user fee act (PDUFA 프두파)<br />
</li>
<li>2007 - FDA Amendments Act (FDAAA 파다)</li>
</ul></li>
<li>CDER responsibility</li>
<li>Investigational New Drug (IND) - how can an unapproved new drug be tested in clinical trials?</li>
<li>IND - need or not? - Lawfully marketed? Off-label? Treat patient?
<ul>
<li>Cover, TOC, Introductory statement and general plan, IB, Tox,</li>
<li>30 day safety review - are the risk to the clinical participant acceptable? adequate safety monitor? - Clinical Hold (deficiency)</li>
</ul></li>
<li>NDA - efficacy, safety - 505(b)(1), 505(b)(2)
<ul>
<li>Evaluation that all requirements for submission have been met and that NDA is well orgenized</li>
<li>Multi-disciplinary approach - Multiple levels</li>
<li>74-day letter</li>
<li>Physician labeling - PLR (Physician labeling reult)</li>
<li>REMS (risk evaluation and mitigations strategies) - REMS for NDA - medication guide, communication plan, implementation</li>
<li>ETASU (elements to assure safeuse) - specific training</li>
</ul></li>
<li>Phase 4 : postmarketing requirements</li>
<li><strong>information on regulation of medical products intended for assisted reproduction</strong></li>
<li>Center for Biologics Evaluation and Research (CBER), Center for Drug Evaluation and Research (CDER), and Center for Devices and Radiological Health (CDRH)</li>
</ul>
</div>
<div id="cdrh-center-for-devices-and-radiological-health" class="section level3">
<h3><span class="header-section-number">15.3.3</span> CDRH (Center for Devices and Radiological Health)</h3>
<ul>
<li>Monica</li>
<li>Medical device - isn’t metabolized.</li>
<li>Classification - Class I (Low risk)-premarket review not required, II (Intermediate) - Petri dishes etc - typically required, III (High) - PMA required.</li>
<li>OB/GYN devices branch - ART devices, vaginal lubricants etc…</li>
<li>21 CFR Parts 884.6100 - 6200 subpart G</li>
<li>Class II - <strong>substantially equivalence</strong> to another marketed devices. - Same intended use, technological characteristics</li>
<li>MOA, Materials/components, Engineering schematics, Design specifications</li>
<li>510(k) submission -
<ul>
<li>Device description,</li>
<li>Labeling (False/misleading claims, instructions for use)</li>
<li>Sterilization (Method, validation, package integrity)</li>
<li>Shelf-life (duration of proposed shelf-life, performance), biocompatibility (patient contact, duration of contact)</li>
<li>Electical safety, electromagnetic compatibility</li>
</ul></li>
<li>ART II special controls - design spec, MEA(Mouse embryo assay), HSSA(human sperm survival assay), endotoxin testing</li>
<li>510(k) outcomes - SE (substantially equivalence) | NES, try again | NSE</li>
<li>Device clearance after SE outcome</li>
<li>De Novo - the newest way for devices to come to market</li>
<li>When come to FDA?
<ul>
<li>Presubmission program for interactive feedback from FDA - regulatory pathway,</li>
<li>Investigation Device Exemption (IDE)</li>
</ul></li>
<li>fda.gov/Tranining/CDRHlearn</li>
</ul>
</div>
<div id="endometriosis-tuesday-expo-theater" class="section level3">
<h3><span class="header-section-number">15.3.4</span> Endometriosis, Tuesday EXPO theater</h3>
<ul>
<li>ESHRE, European Society of Human Reproduction and Embryology (2014),</li>
<li>WES(World Endometriosis Society), Consensus on current management of endometriosis (2013) - <a href="https://www.ncbi.nlm.nih.gov/pubmed/23528916">Consensus on current management of endometriosis.</a></li>
</ul>
<p><strong>The case for surgical diagnosis of endometriosis - Diamond</strong></p>
<ul>
<li>Michael Diamond, MD - Pelvic pain DDX - Endometriosis, fibroids, adenomyosis, adhesions, PID (gynecologic) IBS, Intestitial cystitis, fibromyalgia (non-gynecologic)</li>
<li>Most accurate technique for diagnosis -&gt; laparoscopy with histological confirmation</li>
</ul>
<p><strong>The case for clinical diagnosis of endometriosis - Surrey</strong></p>
<ul>
<li>mean - dianosis, 9.3y, 5 patients</li>
<li>Ultrasound findings - 81% PPV (K - 0.58)</li>
<li>Description of pain (throbbing …)</li>
<li>Symptoms of women undergoing surgery -&gt; dysmenorrha etc (high)</li>
<li>Can response to medication be used to diagnose endometriosis? GnRH agonist or OCs.</li>
<li>Dr. Surrey’s proposed diagnostic algorithm</li>
</ul>
<p><strong>Discussion</strong></p>
<ul>
<li>Diamond - Ix of GnRH agonist - absense of pathology apparent by noninvasive diagnostic modalities</li>
<li>Surrey - Ix of laparoscopy - suspicious or symptomatic adnexal mass, failure to respond to second-line therapy, management of fertility as primary concern, clear evidence of deeply invasive disease</li>
</ul>
</div>
</div>
<div id="scientific-congress-prize-paper-session-2" class="section level2">
<h2><span class="header-section-number">15.4</span> Scientific Congress Prize Paper Session 2</h2>
<div id="o-91-preovulatory-protein-restriction-ppr-disrupted-amino-acid-aa-kinetics-and-mitochondrial-structure-and-function-in-the-rat-oocyte" class="section level3">
<h3><span class="header-section-number">15.4.1</span> O-91 PREOVULATORY PROTEIN RESTRICTION (PPR): DISRUPTED AMINO ACID (AA) KINETICS AND MITOCHONDRIAL STRUCTURE AND FUNCTION IN THE RAT OOCYTE</h3>
<ul>
<li>speaker: Amy Schutt - Baylor College</li>
<li>Maternal dietary intake critically supports the oocyte through maturation, fertilization and until embryo genome activation.</li>
<li>PPR -&gt; profound changes in amino acid metabolism and COC mitochondrial structure and function in the rat.</li>
<li>Amino acid kinetics in the oocyte
<ul>
<li>decreased ability to increase antioxidant precursor production</li>
<li>lack of effective compensation in the setting of protein starvation.</li>
</ul></li>
<li>LP oocyte is vulnerable to oxidative stress as it cannot increase GSH production.
<ul>
<li><strong>abnormal COC mitochondrial ultrastructure</strong> and</li>
<li><strong>altered oocyte expression of genes</strong> related to mitochondrial biogenesis.</li>
</ul></li>
</ul>
</div>
<div id="o-92-effects-of-resveratrol-on-polycystic-ovary-syndrome" class="section level3">
<h3><span class="header-section-number">15.4.2</span> O-92 EFFECTS OF RESVERATROL ON POLYCYSTIC OVARY SYNDROME</h3>
<ul>
<li>speaker: Antoni Duleba (University of California, San Diego)</li>
<li>Hyperandrogenism is the central feature of PCOS</li>
<li>isolated ovarian theca-interstitial cells demonstrated that resveratrol, a natural polyphenol, inhibits mRNA expression of Cyp17a1 and reduces androgen production</li>
<li>evaluated endocrine and metabolic effects of resveratrol on women with PCOS.</li>
<li>Prospective double-blind, randomized, placebo-controlled trial.
<ul>
<li>clinical trial evaluating the effects of resveratrol on PCOS</li>
</ul></li>
<li><strong>Resveratrol significantly reduces serum levels of testosterone and DHEAS</strong>
<ul>
<li>effect on ovarian as well as adrenal androgen production.</li>
<li><strong>improvement of insulin sensitivity</strong> and a decline of insulin level</li>
</ul></li>
</ul>
</div>
<div id="o-93-genome-wide-dna-methylation-changes-in-mouse-zygotes-associated-with-superovulation" class="section level3">
<h3><span class="header-section-number">15.4.3</span> O-93 GENOME-WIDE DNA METHYLATION CHANGES IN MOUSE ZYGOTES ASSOCIATED WITH SUPEROVULATION</h3>
<ul>
<li>speaker: Bo Yu (University of Washington, Seattle)</li>
<li>Assisted Reproductive Technologies (ART) procedures can result in <strong>abnormal methylation of some imprinted genes</strong> in early embryos.</li>
<li><strong>genome-wide effect</strong>
<ul>
<li>to identify <strong>DNA methylome changes</strong> in pre-implantation mouse embryos after <strong>ovarian hyperstimulation</strong></li>
</ul></li>
</ul>
</div>
<div id="o-94-can-we-expect-to-improve-age-at-menopause-predictions-with-repeated-amh-measurements" class="section level3">
<h3><span class="header-section-number">15.4.4</span> O-94 CAN WE EXPECT TO IMPROVE AGE AT MENOPAUSE PREDICTIONS WITH REPEATED AMH MEASUREMENTS?</h3>
<ul>
<li>speaker: Annelien de Kat (University Medical Center Utrecht, Utrecht, Netherlands)</li>
<li>high AMH -&gt; late menopause, low AMH -&gt; early menopause</li>
<li>AMH decline rate</li>
<li>Repeated measures of AMH levels</li>
<li>Anti-M€ullerian hormone (AMH) levels are considered to be an **indicator of ovarian aging</li>
<li>unraveled <strong>longitudinal decline trajectories of AMH with age</strong>.</li>
<li><strong>1,857 women enrolled in the prospective, population-based Doetinchem Cohort Study, with a known age at natural menopause (ANM)</strong></li>
<li><strong>picoAMH assay (AnshLabs) in a total of 7,666 plasma samples</strong></li>
<li>Time to menopause
<ul>
<li>modeled with the use of <strong>mixed model analyses</strong>, taking <strong>non-linear</strong> changes of AMH with age into account for each individual</li>
</ul></li>
<li><strong>longitudinal study</strong> confirms the <strong>overall association of AMH levels with time to menopause</strong>, while taking into account individual AMH changes with time</li>
</ul>
</div>
</div>
<div id="oral-presentation" class="section level2">
<h2><span class="header-section-number">15.5</span> Oral Presentation</h2>
<div id="o-229-the-impact-of-elagolix-on-quality-of-life-in-women-with-endometriosis-associated-pain-results-from-two-randomized-placebo-controlled-studies-using-the-endometriosis-health-profile-questionnaire-hugh-taylor" class="section level3">
<h3><span class="header-section-number">15.5.1</span> O-229 THE IMPACT OF ELAGOLIX ON QUALITY OF LIFE IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN: RESULTS FROM TWO RANDOMIZED, PLACEBO-CONTROLLED STUDIES USING THE ENDOMETRIOSIS HEALTH PROFILE QUESTIONNAIRE (Hugh Taylor)</h3>
<ul>
<li><a href="https://drive.google.com/open?id=0B7BS_yg2ja1EUzlXbDB1VWZDZU0">PPT</a></li>
</ul>
</div>
<div id="o-230-direct-and-indirect-costs-associated-with-endometriosis-related-surgery-among-employed-women-in-the-us" class="section level3">
<h3><span class="header-section-number">15.5.2</span> O-230 DIRECT AND INDIRECT COSTS ASSOCIATED WITH ENDOMETRIOSIS-RELATED SURGERY AMONG EMPLOYED WOMEN IN THE US</h3>
<ul>
<li>Speaker: Ahmed Soliman</li>
<li>surgery 10% endometriosis</li>
<li>treatment of endometriosis by surgery is common</li>
<li>economic burden - MarketScan database</li>
<li>surgery cohort and non-surgery cohort</li>
<li>direct, indirect expenditures, multivariale analysis (GLM)</li>
<li>Hysterectomy $3k, laparoscopy $3k</li>
<li>18k all cause surgery vs 8k non-surgery</li>
<li>observational study</li>
</ul>
</div>
<div id="o-231-new-procedure-for-the-endometriosis-diagnosis" class="section level3">
<h3><span class="header-section-number">15.5.3</span> O-231 NEW PROCEDURE FOR THE ENDOMETRIOSIS DIAGNOSIS</h3>
<ul>
<li>speaker: Xavier Santamaria</li>
<li>mouse model - midventral incision, suture with peritoneal cavity</li>
<li>GFP - endometriotic cells, CD45 - leukocytes</li>
<li>LGR5 - transmembrane orphan receptors - microarray에서 control과 두드러진 차이 보임.</li>
<li>human : in silico study : affymetrix HG U133 Plus 2.0 Arrays</li>
<li>Co-localization with LGR5,
<ul>
<li>none in donor vs high in endometriosis patient</li>
</ul></li>
<li>LGR5+ endometriosis vs LGR5- endometriosis</li>
<li>Monocyte –(differentiation)–&gt; macrophage, monocyte-derived DCs</li>
<li>Conclusion
<ul>
<li>LGR5+ cells co localized in stroma of human eutopic endometrium</li>
<li>immune system, adhesion molecules, migration pathways were differnetially expressed.</li>
</ul></li>
</ul>
</div>
<div id="o-232-elagolix-on-endometrium" class="section level3">
<h3><span class="header-section-number">15.5.4</span> O-232 Elagolix on endometrium</h3>
<ul>
<li><a href="https://drive.google.com/open?id=0B7BS_yg2ja1EaWpDYmxDSnpMX00">PPT</a></li>
</ul>

</div>
</div>
</div>
            </section>

          </div>
        </div>
      </div>
<a href="the-2nd-a3-pharmacometrics-symposium.html" class="navigation navigation-prev " aria-label="Previous page"><i class="fa fa-angle-left"></i></a>
<a href="kscpt-2016-fall.html" class="navigation navigation-next " aria-label="Next page"><i class="fa fa-angle-right"></i></a>
    </div>
  </div>
<script src="libs/gitbook/js/app.min.js"></script>
<script src="libs/gitbook/js/lunr.js"></script>
<script src="libs/gitbook/js/plugin-search.js"></script>
<script src="libs/gitbook/js/plugin-sharing.js"></script>
<script src="libs/gitbook/js/plugin-fontsettings.js"></script>
<script src="libs/gitbook/js/plugin-bookdown.js"></script>
<script src="libs/gitbook/js/jquery.highlight.js"></script>
<script>
require(["gitbook"], function(gitbook) {
gitbook.start({
"sharing": {
"github": false,
"facebook": true,
"twitter": true,
"google": false,
"weibo": false,
"instapper": false,
"vk": false,
"all": ["facebook", "google", "twitter", "weibo", "instapaper"]
},
"fontsettings": {
"theme": "white",
"family": "sans",
"size": 2
},
"edit": {
"link": "https://github.com/shanmdphd/shanmdphd.github.io/edit/master/_ConferencesSource/2016-10-18-ASRM2016.Rmd",
"text": "Edit"
},
"download": ["bookdown.pdf", "bookdown.epub", "bookdown.mobi"],
"toc": {
"collapse": "subsection"
}
});
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://cdn.mathjax.org/mathjax/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    if (location.protocol !== "file:" && /^https?:/.test(script.src))
      script.src  = script.src.replace(/^https?:/, '');
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>
</body>

</html>
